Final PAPILLON trial results show Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) plus chemotherapy achieved a 34.3-month median overall survival in EGFR exon 20 insertion-positive NSCLC — the longest reported to date in this historically hard-to-treat population.
Results from the AstraZeneca Enhertu DESTINY-Lung04 Trial show a 37% reduction in risk of disease progression or death, establishing first-line efficacy for T-DXd in HER2-mutant non-small cell lung cancer.
Roche’s collaborator MediLink reported phase III TAISHAN-302 data showing Tam-Peli (tambotatug pelitecan) reduced the risk of death by 54% versus topotecan in Chinese patients with relapsed small-cell lung cancer, meeting its primary endpoint with a favorable safety profile.
AstraZeneca has officially stopped its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy in first-line metastatic NSCLC following a recommendation from the Independent Data Monitoring Committee.
AstraZeneca has secured exclusive worldwide rights to Zegfrovy (sunvozertinib), Dizal Pharmaceutical’s oral EGFR inhibitor for EGFR exon 20 insertion non-small cell lung cancer, in a deal worth up to $1.5 billion. The agreement strengthens AstraZeneca’s EGFR-mutated lung cancer portfolio ahead of potential first-line expansion.
Roche’s next-generation KRAS G12C inhibitor, divarasib, has achieved statistical significance in a global head-to-head Phase III trial against sotorasib and adagrasib for advanced non-small cell lung cancer.
Pfizer has announced topline Phase 3 results from its SigVie-002 study evaluating the investigational antibody-drug conjugate sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer.
Updated data from the CHRYSALIS-2 study reveals that Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® combination achieves a historic median overall survival of 41.0 months as a first-line therapy for atypical EGFR-mutated advanced non-small cell lung cancer.
Landmark seven-year results from Pfizer’s CROWN study show LORBRENA (lorlatinib) reduces the risk of disease progression or death by 81% in ALK+ NSCLC, setting a new standard for oncology care.
Eli Lilly’s Retevmo (selpercatinib) has shown promising results as an adjuvant therapy for early-stage lung cancer. The Phase 3 LIBRETTO-432 trial revealed that Retevmo adjuvant therapy significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer (NSCLC), marking a breakthrough for this rare molecular subtype affecting 1-2% of lung cancer cases.
